Back to SWTOYView full pipeline
Phase 2
Development Phase
0
Upcoming Catalysts
0
Historical Events
1
Regulatory Approvals
No Catalysts Found
No catalyst events have been recorded for this drug yet.
Competitive Landscape
0 competitors in Cytopenia
View Full LandscapeDrug Information
Patent & Exclusivity
No patent data available. Pre-approval drugs may not have Orange Book listings.
Regulatory Approvals
EMAPending
Gamifant
Gamifant is indicated for the treatment of paediatric patients aged under 18 years with primary haemophagocytic lymphohistiocytosis (HLH).
OrphanPRIME
View on EMADrug Science
Mechanism of action & safety profile
Related Pipeline
AvatrombopagPhase 3
Chemotherapy-induced Thrombocytopenia
Avatrombopag Oral TabletPhase 3
Immune Thrombocytopenia
PacritinibPhase 2
Waldenström Macroglobulinemia
Loncastuximab Tesirine and EpcoritamabPhase 2
Aggressive Diffuse Large B-cell Lymphoma
Fludarabine and DexamethasonePhase 2
Primary Immune Regulatory Disorder
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts